Lineage Cell Therapeutics マネジメント
マネジメント 基準チェック /24
Lineage Cell Therapeutics' CEO is Brian Culley, appointed in Sep 2018, has a tenure of 6.17 years. total yearly compensation is $2.91M, comprised of 22% salary and 78% bonuses, including company stock and options. directly owns 0.082% of the company’s shares, worth $126.32K. The average tenure of the management team and the board of directors is 3.8 years and 8 years respectively.
主要情報
Brian Culley
最高経営責任者
US$2.9m
報酬総額
| CEO給与比率 | 22.0% |
| CEO在任期間 | 6.2yrs |
| CEOの所有権 | 0.08% |
| 経営陣の平均在職期間 | 3.8yrs |
| 取締役会の平均在任期間 | 8yrs |
CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$24m |
| Mar 31 2024 | n/a | n/a | -US$24m |
| Dec 31 2023 | US$3m | US$640k | -US$21m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$22m |
| Mar 31 2023 | n/a | n/a | -US$24m |
| Dec 31 2022 | US$2m | US$609k | -US$26m |
| Sep 30 2022 | n/a | n/a | -US$49m |
| Jun 30 2022 | n/a | n/a | -US$51m |
| Mar 31 2022 | n/a | n/a | -US$49m |
| Dec 31 2021 | US$3m | US$580k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$1m | US$552k | -US$21m |
| Sep 30 2020 | n/a | n/a | -US$27m |
| Jun 30 2020 | n/a | n/a | -US$36m |
| Mar 31 2020 | n/a | n/a | -US$59m |
| Dec 31 2019 | US$773k | US$536k | -US$12m |
| Sep 30 2019 | n/a | n/a | -US$52m |
| Jun 30 2019 | n/a | n/a | US$31m |
| Mar 31 2019 | n/a | n/a | US$57m |
| Dec 31 2018 | US$3m | US$155k | -US$46m |
報酬と市場: Brian's total compensation ($USD2.91M) is above average for companies of similar size in the US market ($USD1.48M).
報酬と収益: Brian's compensation has increased whilst the company is unprofitable.
CEO（最高経営責任者
Brian Culley (53 yo)
6.2yrs
在職期間
US$2,905,130
報酬
Mr. Brian M. Culley, M.A., M.B.A., served as Interim Chief Financial Officer, Principal Financial Officer at Lineage Cell Therapeutics, Inc. since July 8, 2022 until November 14, 2022. He served as Interim...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 6.2yrs | US$2.91m | 0.082% $ 126.3k | |
| CFO & Principal Financial and Accounting Officer | 2yrs | US$738.86k | 0.0056% $ 8.6k | |
| General Counsel & Company Secretary | 3.2yrs | US$1.21m | 0.0038% $ 5.9k | |
| Director of Investor Relations | no data | データなし | データなし | |
| Vice President of Corporate Development | less than a year | データなし | データなし | |
| Consultant | 3.8yrs | US$668.25k | データなし | |
| President & CEO of OncoCyte Corporation | no data | US$654.85k | データなし | |
| Chief Executive Officer of Cell Cure Neurosciences | no data | データなし | データなし | |
| Senior Director of Finance & Controller | 5.2yrs | データなし | データなし | |
| Vice President of Regulatory Affairs & Quality Control | 29.8yrs | US$90.00k | データなし |
3.8yrs
平均在職期間
53yo
平均年齢
経験豊富な経営陣: LCTX's management team is considered experienced (3.8 years average tenure).
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 6.2yrs | US$2.91m | 0.082% $ 126.3k | |
| Independent Director | 5.7yrs | US$130.50k | 0.084% $ 129.5k | |
| Independent Director | 9.9yrs | US$138.00k | 0.046% $ 71.4k | |
| Independent Director | 3.5yrs | US$128.00k | 0.0053% $ 8.2k | |
| Independent Director | 15.3yrs | US$141.13k | 0.046% $ 71.5k | |
| Independent Director | 10.6yrs | US$148.00k | 0.0083% $ 12.7k | |
| Independent Chairman | 10.1yrs | US$151.13k | 0.14% $ 210.9k | |
| Independent Director | 3.6yrs | US$128.00k | 0.019% $ 28.5k |
8.0yrs
平均在職期間
63yo
平均年齢
経験豊富なボード: LCTX's board of directors are considered experienced (8 years average tenure).